Search Results - "VERNILLET, Laurent"

Effect of cenobamate on the single‐dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects by Greene, Stephen A., Kwak, Charles, Kamin, Marc, Vernillet, Laurent, Glenn, Kelli J., Gabriel, Lana, Kim, Hong Wook

“…This study was designed to evaluate the effects of cenobamate, an antiseizure medication for focal seizures, on the pharmacokinetics of cytochrome P450 probes…”
Get full text

P154 - Absorption, distribution, metabolism, and excretion of the novel antiepileptic drug cenobamate: mass balance following oral administration in healthy male subjects by Glenn, Kelli J., Greene, Stephen, Kim, Hong-Wook, Melnick, Susan M., Vernillet, Laurent

Get full text

Metabolism and Excretion of [14C] Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase, in Healthy Male Subjects by Grabowski, Brian A., Khosravan, Reza, Vernillet, Laurent, Mulford, Darcy J.

“…Absorption, metabolism, and excretion of one 80 mg oral dose of [14C] febuxostat ([thiazole‐4‐14C] 2‐[3‐cyano‐4‐isobutoxyphenyl]‐4‐methyl‐5‐thiazolecarboxylic…”
Get full text

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor by WONG, Harvey, VERNILLET, Laurent, HOEFLICH, Klaus P, YONGCHANG SHI, AFTAB, Blake T, AOYAMA, Ron, TAN LAM, Sanh, BELVIN, Marcia, PRESCOTT, John, PETERSON, Amy, WARE, Joseph A, LEE, Lillian, MARTINI, Jean-Francois, PEIWEN YU, CONGFEN LI, DEL ROSARIO, Geoffrey, CHOO, Edna F

“…GDC-0973 is a potent and selective mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor…”
Get full text

Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects by Khosravan, Reza, Grabowski, Brian, Wu, Jing‐Tao, Joseph‐Ridge, Nancy, Vernillet, Laurent

“…What is already known about this subject • Febuxostat is a novel nonpurine selective inhibitor of xanthine oxidase. What this study adds • This is the first…”
Get full text

Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects by KHOSRAVAN, Reza, GRABOWSKI, Brian A, WU, Jing-Tao, JOSEPH-RIDGE, Nancy, VERNILLET, Laurent

“…Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase currently being developed for the management of hyperuricemia in patients with gout…”
Get full text

The Effect of Age and Gender on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase by Khosravan, Reza, Kukulka, Michael J., Wu, Jing-Tao, Joseph-Ridge, Nancy, Vernillet, Laurent

“…Febuxostat is a novel nonpurine selective inhibitor of xanthine oxidase, which is currently being developed for the management of hyperuricemia in patients…”
Get full text

Metabolism of Irinotecan (CPT-11) by CYP3A4 and CYP3A5 in Humans by Santos, A, Zanetta, S, Cresteil, T, Deroussent, A, Pein, F, Raymond, E, Vernillet, L, Risse, M L, Boige, V, Gouyette, A, Vassal, G

“…7-Ethyl-10[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11), a DNA topoisomerase I inhibitor, undergoes several metabolic pathways to generate…”
Get full text

The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase by Khosravan, Reza, Grabowski, Brian A., Mayer, Michael D., Wu, Jing-Tao, Joseph-Ridge, Nancy, Vernillet, Laurent

“…To assess the effect of hepatic impairment on the pharmacokinetics, pharmacodynamics, and safety of febuxostat at steady state, multiple once‐daily 80‐mg oral…”
Get full text

Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction by Raymond, Eric, Boige, Valérie, Faivre, Sandrine, Sanderink, Ger-Jan, Rixe, Olivier, Vernillet, Laurent, Jacques, Christian, Gatineau, Michel, Ducreux, Michel, Armand, Jean-Pierre

“…To determine the recommended dose (RD) and the pharmacokinetic profile of irinotecan and its metabolites in cancer patients with hyperbilirubinemia. Patients…”
Get full text

Pharmacokinetics of Cenobamate (YKP3089): Results From Single and Multiple Oral Rising-Dose Studies in Healthy Subjects (P5.280) by Vernillet, Laurent, Kamin, Marc

“…Abstract only…”
Get full text

A Review of the Pharmacokinetic Properties of Cenobamate (YKP3089), a Novel Antiepileptic Drug for the Treatment of Uncontrolled Focal Seizures in Adults (1041) by Greene, Stephen A., Vernillet, Laurent

“…Abstract only…”
Get full text

Phase I Dose-Finding Study of a New Taxane, RPR 109881A, Administered as a One-Hour Intravenous Infusion Days 1 and 8 to Patients With Advanced Solid Tumors by GELMON, Karen A, LATREILLE, Jean, BESENVAL, Michele, EISENHAUER, Elizabeth, TOLCHER, Anthony, GENIER, Luc, FISHER, Bryn, FORAND, Dominique, D'ALOISIO, Susan, VERNILLET, Laurent, DAIGNEAULT, Luc, LEBECQ, Ann

“…To define the maximum-tolerated dose, recommended phase II dose (RD), dose-limiting toxicity (DLT), and pharmacokinetics of a novel taxane, RPR 109881A,…”
Get full text

Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending‐Dose Studies in Healthy Subjects by Vernillet, Laurent, Greene, Stephen A., Kamin, Marc

“…Cenobamate (YKP3089) is an antiepileptic drug recently approved by the Food and Drug Administration for the treatment of focal (partial‐onset) seizures in…”
Get full text

The Pharmacokinetics of Cenobamate in Special Populations (P1.5-034) by Greene, Stephen, Orlinski, Laurie, Streicher, Caroline, Vernillet, Laurent

“…Abstract only…”
Get full text

Pharmacokinetic, Metabolic, and Pharmacodynamic Profiles in a Dose-Escalating Study of Irinotecan and Cisplatin by DE JONGE, M. J. A, VERWEIJ, J, DE BRUIJN, P, BROUWER, E, MATHIJSSEN, R. H. J, VAN ALPHEN, R. J, DE BOER-DENNERT, M. M, VERNILLET, L, JACQUES, C, SPORREBOOM, A

“…To investigate the pharmacokinetics and pharmacodynamics of irinotecan and cisplatin administered once every 3 weeks in a dose-escalating study in patients…”
Get full text

Phase I and Pharmacokinetic Study of Irinotecan Administered as a Low-Dose, Continuous Intravenous Infusion Over 14 Days in Patients With Malignant Solid Tumors by HERBEN, V. M. M, SCHELLENS, J. H. M, SWART, M, GRUIA, G, VERNILLET, L, BEIJNEN, J. H, TEN BOKKEL HUININK, W. W

“…To evaluate the feasibility of administering irinotecan as a continuous intravenous infusion for 14 to 21 days. Patients with solid tumors refractory to…”
Get full text

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation by Clancy, J P, Rowe, Steven M, Accurso, Frank J, Aitken, Moira L, Amin, Raouf S, Ashlock, Melissa A, Ballmann, Manfred, Boyle, Michael P, Bronsveld, Inez, Campbell, Preston W, De Boeck, Kris, Donaldson, Scott H, Dorkin, Henry L, Dunitz, Jordan M, Durie, Peter R, Jain, Manu, Leonard, Anissa, McCoy, Karen S, Moss, Richard B, Pilewski, Joseph M, Rosenbluth, Daniel B, Rubenstein, Ronald C, Schechter, Michael S, Botfield, Martyn, Ordoñez, Claudia L, Spencer-Green, George T, Vernillet, Laurent, Wisseh, Steve, Yen, Karl, Konstan, Michael W

“…VX-809, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, has been shown to increase the cell surface density of functional F508del-CFTR…”
Get more information

A Phase I Study of Docetaxel Plus Cyclophosphamide in Solid Tumors followed by a Phase II Study as First-Line Therapy in Metastatic Breast Cancer by Trent, Jonathan C, Valero, Vicente, Booser, Daniel J, Esparza-Guerra, Laura T, Ibrahim, Nuhad, Rahman, Zia, Vernillet, Laurent, Patel, Shreyaskumar, David, Cynthia L, Murray, James L, Cristofanilli, Massimo, Hortobagyi, Gabriel N

“…Purpose: In Phase I, the purpose was to determine the maximum tolerated dose and pharmacokinetics of docetaxel plus cyclophosphamide (DC) with and without…”
Get full text

Mass Balance, Metabolism, and Excretion of Cenobamate, a New Antiepileptic Drug, After a Single Oral Administration in Healthy Male Subjects by Vernillet, Laurent, Greene, Stephen A., Kim, Hong Wook, Melnick, Susan M., Glenn, Kelli

“…Background and Objective Cenobamate is an antiepileptic drug for the treatment of partial-onset seizures. The current study was designed to assess the mass…”
Get full text